- Home
- SJT vs FENC Comparison
SJT vs FENC Comparison
Compare SJT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$12.47
Company Overview
Basic Information| Metric | SJT | FENC |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | 495 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 430.3M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | SJT | FENC |
|---|---|---|
| Price | $3.08 | $12.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 190.2K | ★ 262.7K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $206.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.37 | $5.65 |
| 52 Week High | $6.61 | $13.25 |
Technical Indicators
Market Signals| Indicator | SJT | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 63.51 | 60.00 |
| Support Level | $2.57 | $9.74 |
| Resistance Level | $3.10 | N/A |
| Average True Range (ATR) | 0.20 | 0.59 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 86.27 | 81.15 |
Price Performance
Historical Comparison SJT
FENC
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.